Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

COSM vs HROW vs NTRB vs XTLB vs CODA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
COSM
Cosmos Health Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$11M
5Y Perf.-91.5%
HROW
Harrow Health, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.45B
5Y Perf.+287.0%
NTRB
Nutriband Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$46M
5Y Perf.-29.4%
XTLB
XTL Biopharmaceuticals Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$294K
5Y Perf.-82.5%
CODA
Coda Octopus Group, Inc.

Aerospace & Defense

IndustrialsNASDAQ • US
Market Cap$134M
5Y Perf.+41.0%

COSM vs HROW vs NTRB vs XTLB vs CODA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
COSM logoCOSM
HROW logoHROW
NTRB logoNTRB
XTLB logoXTLB
CODA logoCODA
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnologyAerospace & Defense
Market Cap$11M$1.45B$46M$294K$134M
Revenue (TTM)$60M$272M$2M$451K$28M
Net Income (TTM)$-19M$-5M$-8M$-1M$4M
Gross Margin11.4%75.1%24.9%26.4%66.3%
Operating Margin-23.9%11.2%-408.4%-481.6%17.4%
Forward P/E82.9x22.5x
Total Debt$12M$252M$210K$138K$395K
Cash & Equiv.$315K$73M$5M$371K$29M

COSM vs HROW vs NTRB vs XTLB vs CODALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

COSM
HROW
NTRB
XTLB
CODA
StockOct 21May 26Return
Cosmos Health Inc. (COSM)1008.5-91.5%
Harrow Health, Inc. (HROW)100387.0+287.0%
Nutriband Inc. (NTRB)10070.6-29.4%
XTL Biopharmaceutic… (XTLB)10017.5-82.5%
Coda Octopus Group,… (CODA)100141.0+41.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: COSM vs HROW vs NTRB vs XTLB vs CODA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CODA leads in 5 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Cosmos Health Inc. is the stronger pick specifically for dividend income and shareholder returns. HROW also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
COSM
Cosmos Health Inc.
The Income Pick

COSM is the #2 pick in this set and the best alternative if dividends is your priority.

  • 92.4% yield; 1-year raise streak; the other 4 pay no meaningful dividend
Best for: dividends
HROW
Harrow Health, Inc.
The Growth Play

HROW ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 36.4%, EPS growth 71.4%, 3Y rev CAGR 45.4%
  • 9.1% 10Y total return vs CODA's 8.4%
  • 36.4% revenue growth vs XTLB's -173.2%
Best for: growth exposure and long-term compounding
NTRB
Nutriband Inc.
The Income Pick

NTRB is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.20
Best for: income & stability
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick

Among these 5 stocks, XTLB doesn't own a clear edge in any measured category.

Best for: healthcare exposure
CODA
Coda Octopus Group, Inc.
The Defensive Pick

CODA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 1.00, Low D/E 0.7%, current ratio 8.86x
  • Beta 1.00, current ratio 8.86x
  • Better valuation composite
  • 14.8% margin vs NTRB's -404.1%
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthHROW logoHROW36.4% revenue growth vs XTLB's -173.2%
ValueCODA logoCODABetter valuation composite
Quality / MarginsCODA logoCODA14.8% margin vs NTRB's -404.1%
Stability / SafetyCODA logoCODABeta 1.00 vs HROW's 2.13, lower leverage
DividendsCOSM logoCOSM92.4% yield; 1-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)CODA logoCODA+78.9% vs XTLB's -50.9%
Efficiency (ROA)CODA logoCODA6.6% ROA vs NTRB's -101.9%, ROIC 11.2% vs -270.2%

COSM vs HROW vs NTRB vs XTLB vs CODA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

COSMCosmos Health Inc.
FY 2024
Pharma manufacturing
100.0%$865,373
HROWHarrow Health, Inc.
FY 2025
Product Sales Net
99.9%$272M
Other Revenues
0.1%$394,000
NTRBNutriband Inc.

Segment breakdown not available.

XTLBXTL Biopharmaceuticals Ltd.

Segment breakdown not available.

CODACoda Octopus Group, Inc.
FY 2025
Equipment Sales
71.3%$14M
Service
17.3%$4M
Equipment Rentals
7.3%$1M
Software Sales
4.0%$811,912

COSM vs HROW vs NTRB vs XTLB vs CODA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHROWLAGGINGXTLB

Income & Cash Flow (Last 12 Months)

Evenly matched — HROW and CODA each lead in 2 of 6 comparable metrics.

HROW is the larger business by revenue, generating $272M annually — 603.8x XTLB's $451,000. CODA is the more profitable business, keeping 14.8% of every revenue dollar as net income compared to NTRB's -4.0%. On growth, COSM holds the edge at +37.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCOSM logoCOSMCosmos Health Inc.HROW logoHROWHarrow Health, In…NTRB logoNTRBNutriband Inc.XTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…
RevenueTrailing 12 months$60M$272M$2M$451,000$28M
EBITDAEarnings before interest/tax-$13M$59M-$8M-$1M$6M
Net IncomeAfter-tax profit-$19M-$5M-$8M-$1M$4M
Free Cash FlowCash after capex-$10M$73M-$5M$0$7M
Gross MarginGross profit ÷ Revenue+11.4%+75.1%+24.9%+26.4%+66.3%
Operating MarginEBIT ÷ Revenue-23.9%+11.2%-4.1%-4.8%+17.4%
Net MarginNet income ÷ Revenue-31.0%-1.9%-4.0%-2.3%+14.8%
FCF MarginFCF ÷ Revenue-17.2%+26.8%-2.5%-3.7%+24.6%
Rev. Growth (YoY)Latest quarter vs prior year+37.9%+33.3%-37.6%+28.8%
EPS Growth (YoY)Latest quarter vs prior year+62.2%-5.3%+84.4%+20.0%+3.0%
Evenly matched — HROW and CODA each lead in 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — COSM and HROW and XTLB and CODA each lead in 1 of 4 comparable metrics.
MetricCOSM logoCOSMCosmos Health Inc.HROW logoHROWHarrow Health, In…NTRB logoNTRBNutriband Inc.XTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…
Market CapShares × price$11M$1.5B$46M$293,767$134M
Enterprise ValueMkt cap + debt − cash$23M$1.6B$42M$60,767$106M
Trailing P/EPrice ÷ TTM EPS-0.30x-278.93x-1.47x-0.28x32.16x
Forward P/EPrice ÷ next-FY EPS est.82.86x22.45x
PEG RatioP/E ÷ EPS growth rate7.51x
EV / EBITDAEnterprise value multiple17.85x
Price / SalesMarket cap ÷ Revenue0.20x5.34x22.66x0.65x5.05x
Price / BookPrice ÷ Book value/share0.27x27.56x6.61x0.05x2.30x
Price / FCFMarket cap ÷ FCF22.20x
Evenly matched — COSM and HROW and XTLB and CODA each lead in 1 of 4 comparable metrics.

Profitability & Efficiency

CODA leads this category, winning 6 of 9 comparable metrics.

CODA delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-118 for NTRB. CODA carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HROW's 4.84x. On the Piotroski fundamental quality scale (0–9), CODA scores 7/9 vs XTLB's 3/9, reflecting strong financial health.

MetricCOSM logoCOSMCosmos Health Inc.HROW logoHROWHarrow Health, In…NTRB logoNTRBNutriband Inc.XTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…
ROE (TTM)Return on equity-80.1%-10.1%-118.3%-25.5%+7.2%
ROA (TTM)Return on assets-26.7%-1.4%-101.9%-17.7%+6.6%
ROICReturn on invested capital-28.9%+9.5%-2.7%-54.1%+11.2%
ROCEReturn on capital employed-44.3%+10.2%-125.5%-50.7%+8.1%
Piotroski ScoreFundamental quality 0–934337
Debt / EquityFinancial leverage0.48x4.84x0.03x0.03x0.01x
Net DebtTotal debt minus cash$12M$179M-$4M-$233,000-$28M
Cash & Equiv.Liquid assets$315,105$73M$5M$371,000$29M
Total DebtShort + long-term debt$12M$252M$209,629$138,000$394,932
Interest CoverageEBIT ÷ Interest expense-9.42x0.53x-369.11x-13.31x
CODA leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HROW leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HROW five years ago would be worth $47,797 today (with dividends reinvested), compared to $547 for COSM. Over the past 12 months, CODA leads with a +78.9% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors HROW at 12.7% vs COSM's -52.8% — a key indicator of consistent wealth creation.

MetricCOSM logoCOSMCosmos Health Inc.HROW logoHROWHarrow Health, In…NTRB logoNTRBNutriband Inc.XTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…
YTD ReturnYear-to-date-32.0%-21.8%-14.4%+11.3%+25.1%
1-Year ReturnPast 12 months-17.0%+58.8%-34.4%-50.9%+78.9%
3-Year ReturnCumulative with dividends-89.5%+43.0%+10.8%-45.7%+34.5%
5-Year ReturnCumulative with dividends-94.5%+378.0%-34.0%-80.4%+49.7%
10-Year ReturnCumulative with dividends+37.8%+914.3%-34.0%-87.3%+844.4%
CAGR (3Y)Annualised 3-year return-52.8%+12.7%+3.5%-18.4%+10.4%
HROW leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — HROW and CODA each lead in 1 of 2 comparable metrics.

CODA is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than HROW's 2.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HROW currently trades 71.2% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCOSM logoCOSMCosmos Health Inc.HROW logoHROWHarrow Health, In…NTRB logoNTRBNutriband Inc.XTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…
Beta (5Y)Sensitivity to S&P 5001.72x2.13x1.20x1.71x1.00x
52-Week HighHighest price in past year$1.32$54.85$11.68$10.28$17.28
52-Week LowLowest price in past year$0.28$21.12$3.42$1.05$5.98
% of 52W HighCurrent price vs 52-week peak+26.5%+71.2%+32.4%+26.0%+68.9%
RSI (14)Momentum oscillator 0–10048.654.650.857.048.6
Avg Volume (50D)Average daily shares traded793K733K11K2.4M256K
Evenly matched — HROW and CODA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — COSM and NTRB each lead in 1 of 1 comparable metric.

Analyst consensus: HROW as "Buy", CODA as "Buy". Consensus price targets imply 93.8% upside for HROW (target: $76) vs 17.6% for CODA (target: $14). COSM is the only dividend payer here at 92.44% yield — a key consideration for income-focused portfolios.

MetricCOSM logoCOSMCosmos Health Inc.HROW logoHROWHarrow Health, In…NTRB logoNTRBNutriband Inc.XTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$75.67$14.00
# AnalystsCovering analysts101
Dividend YieldAnnual dividend ÷ price+92.4%
Dividend StreakConsecutive years of raises1010
Dividend / ShareAnnual DPS$0.32
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%0.0%
Evenly matched — COSM and NTRB each lead in 1 of 1 comparable metric.
Key Takeaway

CODA leads in 1 of 6 categories (Profitability & Efficiency). HROW leads in 1 (Total Returns). 4 tied.

Best OverallHarrow Health, Inc. (HROW)Leads 1 of 6 categories
Loading custom metrics...

COSM vs HROW vs NTRB vs XTLB vs CODA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is COSM or HROW or NTRB or XTLB or CODA a better buy right now?

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -4. 8% for Nutriband Inc. (NTRB). Coda Octopus Group, Inc. (CODA) offers the better valuation at 32. 2x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — COSM or HROW or NTRB or XTLB or CODA?

On forward P/E, Coda Octopus Group, Inc.

is actually cheaper at 22. 5x.

03

Which is the better long-term investment — COSM or HROW or NTRB or XTLB or CODA?

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -94. 5% for Cosmos Health Inc. (COSM). Over 10 years, the gap is even starker: HROW returned +914. 3% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — COSM or HROW or NTRB or XTLB or CODA?

By beta (market sensitivity over 5 years), Coda Octopus Group, Inc.

(CODA) is the lower-risk stock at 1. 00β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 112% more volatile than CODA relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — COSM or HROW or NTRB or XTLB or CODA?

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus -4. 8% for Nutriband Inc. (NTRB). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to -160. 6% for Nutriband Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — COSM or HROW or NTRB or XTLB or CODA?

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -404. 1% for Nutriband Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is COSM or HROW or NTRB or XTLB or CODA more undervalued right now?

On forward earnings alone, Coda Octopus Group, Inc.

(CODA) trades at 22. 5x forward P/E versus 82. 9x for Harrow Health, Inc. — 60. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

08

Which pays a better dividend — COSM or HROW or NTRB or XTLB or CODA?

In this comparison, COSM (92.

4% yield) pays a dividend. HROW, NTRB, XTLB, CODA do not pay a meaningful dividend and should not be held primarily for income.

09

Is COSM or HROW or NTRB or XTLB or CODA better for a retirement portfolio?

For long-horizon retirement investors, Coda Octopus Group, Inc.

(CODA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +844. 4% 10Y return). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CODA: +844. 4%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between COSM and HROW and NTRB and XTLB and CODA?

These companies operate in different sectors (COSM (Healthcare) and HROW (Healthcare) and NTRB (Healthcare) and XTLB (Healthcare) and CODA (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: COSM is a small-cap income-oriented stock; HROW is a small-cap high-growth stock; NTRB is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; CODA is a small-cap high-growth stock. COSM pays a dividend while HROW, NTRB, XTLB, CODA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

COSM

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 18%
  • Dividend Yield > 36.9%
Run This Screen
Stocks Like

HROW

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 16%
  • Gross Margin > 45%
Run This Screen
Stocks Like

NTRB

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Stocks Like

XTLB

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 15%
Run This Screen
Stocks Like

CODA

High-Growth Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform COSM and HROW and NTRB and XTLB and CODA on the metrics below

Revenue Growth>
%
(COSM: 37.9% · HROW: 33.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.